Assetmark Inc. lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 48,112 shares of the company’s stock after selling 2,042 shares during the period. Assetmark Inc.’s holdings in IDEXX Laboratories were worth $12,012,000 at the end of the most recent reporting period.
A number of other large investors have also recently modified their holdings of the business. Highbridge Capital Management LLC lifted its holdings in IDEXX Laboratories by 1,033.3% during the third quarter. Highbridge Capital Management LLC now owns 17,000 shares of the company’s stock valued at $4,244,000 after purchasing an additional 15,500 shares in the last quarter. AlphaStar Capital Management LLC purchased a new position in shares of IDEXX Laboratories in the third quarter worth $202,000. Maryland Capital Management purchased a new position in shares of IDEXX Laboratories in the third quarter worth $225,000. Kepos Capital LP lifted its holdings in shares of IDEXX Laboratories by 5.0% in the third quarter. Kepos Capital LP now owns 17,808 shares of the company’s stock worth $4,446,000 after buying an additional 851 shares in the last quarter. Finally, Kornitzer Capital Management Inc. KS lifted its holdings in shares of IDEXX Laboratories by 567.0% in the third quarter. Kornitzer Capital Management Inc. KS now owns 132,836 shares of the company’s stock worth $33,164,000 after buying an additional 112,920 shares in the last quarter. 91.14% of the stock is currently owned by institutional investors and hedge funds.
In related news, Director Rebecca M. Henderson sold 3,504 shares of the business’s stock in a transaction on Tuesday, November 27th. The shares were sold at an average price of $194.92, for a total value of $682,999.68. Following the sale, the director now owns 22,200 shares in the company, valued at $4,327,224. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jacqueline Studer sold 3,313 shares of the business’s stock in a transaction on Tuesday, November 6th. The stock was sold at an average price of $201.27, for a total transaction of $666,807.51. The disclosure for this sale can be found here. Insiders own 2.56% of the company’s stock.
IDXX stock opened at $190.01 on Friday. IDEXX Laboratories, Inc. has a one year low of $154.88 and a one year high of $256.22. The firm has a market capitalization of $16.97 billion, a PE ratio of 57.93, a P/E/G ratio of 2.50 and a beta of 0.84.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Thursday, November 1st. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $0.97 by $0.08. IDEXX Laboratories had a net margin of 15.19% and a negative return on equity of 994.76%. The company had revenue of $545.00 million for the quarter, compared to analysts’ expectations of $545.66 million. During the same quarter in the previous year, the business posted $0.76 earnings per share. IDEXX Laboratories’s quarterly revenue was up 10.8% on a year-over-year basis. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 4.19 EPS for the current fiscal year.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Recommended Story: Fundamental Analysis and Choosing Stocks
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.